Granahan's Investment Rebalancing
Granahan Investment Management Boosts OrthoPediatrics, CAVA, Allegro Stakes While Trimming Others
Anonymous
Key Points
1
Granahan's OrthoPediatrics stake value reached about $14.231 million at period end after acquiring 232,760 shares for a total of 896,741.
2
CEO Thomas E. Hogan of Cellebrite DI sold 103,188 shares for about $1.626 million (average price $15.76), in a related executive-sale update.
3
Granahan raised its CAVA Group holdings by 31.7% to 303,891 shares, representing roughly 0.26% of its portfolio and about $24.585 million in value, ranking it 21st among holdings.
4
Granahan reduced its JFrog stake by 13.6% to 130,103 shares (about 0.11% of the company), valued at roughly $6.106 million for the period.
5
Granahan increased Allegro MicroSystems to 215,001 shares (up 139.3%, about $6.779 million in value); in related Allegro activity, CAO Roald Graham Webster sold 5,217 shares in a separate trade.
Granahan Investment Management LLC made bold moves in the first quarter, sharply increasing stakes in OrthoPediatrics, CAVA Group, and Allegro MicroSystems while cutting its position in Cellebrite DI by nearly half, according to Watchlist News.
The Massachusetts-based firm's biggest swing was in Allegro MicroSystems, where it grew its position by 139.3% to 215,001 shares — worth roughly $6.78 million. The moves signal a broad strategic rebalancing across healthcare and tech names.
OrthoPediatrics and CAVA Get Big Boosts from Granahan
Granahan added 232,760 shares of OrthoPediatrics Corp. in Q1, lifting its total to 896,741 shares, according to Watchlist News. That stake is now worth about $14.23 million. The firm grew its holding by 35.1% in a single quarter.
CAVA Group also got a major bump. Granahan raised its position by 31.7% to 303,891 shares, valued at roughly $24.59 million. CAVA now ranks 21st among the firm's holdings, making up about 0.26% of its total portfolio, Watchlist News reported.
Granahan Slashes Cellebrite Stake by 43% Amid CEO Share Sale
Granahan sold 1,317,374 shares of Cellebrite DI Ltd. in Q1, cutting its stake by 43.1% to 1,739,644 shares, according to Watchlist News. The firm still holds about $23.97 million in the digital intelligence company.
The trimming came alongside an executive sale at Cellebrite. CEO Thomas E. Hogan sold 103,188 shares at an average price of $15.76 per share, pulling in about $1.63 million. Insider sales of that size can signal caution at the executive level.
Allegro MicroSystems Surges 139% in Granahan's Portfolio
Granahan nearly doubled its Allegro MicroSystems position — up 139.3% — to reach 215,001 shares worth around $6.78 million, per Watchlist News. The move makes Allegro one of the firm's fastest-growing positions by share count this quarter.
Separately, Allegro's Chief Accounting Officer Roald Graham Webster sold 5,217 shares in a related trade, according to Watchlist News. Granahan also raised its Stoke Therapeutics stake by 75.3%, to a holding valued at $10.93 million, rounding out its healthcare bets.
JFrog and Zymeworks See Smaller Adjustments in the Mix
Not every position grew. Granahan cut its JFrog Ltd. stake by 13.6% to 130,103 shares, worth about $6.11 million. That holding now equals roughly 0.11% of JFrog's total outstanding shares, Watchlist News noted.
Granahan also nudged up its Zymeworks position by 11.7%, adding 26,365 shares for a total of 250,773, according to Ticker Report. That smaller move shows the firm is still adding selectively in biotech, even as it cuts elsewhere.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
27
Articles
19
Reach
46
Topics
A
AnonymousAuthor
